# Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

> **NCT07033481** · PHASE2 · RECRUITING · sponsor: **EIP Pharma Inc** · enrollment: 20 (estimated)

## Conditions studied

- Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

## Interventions

- **DRUG:** Neflamapimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07033481
- **Lead sponsor:** EIP Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-02
- **Primary completion:** 2026-09
- **Final completion:** 2026-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07033481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07033481, "Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07033481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*